trial
as of 2026-07-01Randomized Withdrawal Study in Patients With Schizophrenia
NCTId NCT06961968
at a glance
Phase 3 · Recruiting
Enrollment 400 (estimated)
Sponsored by Vanda Pharmaceuticals
Primary completion 2027-11
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Recruiting
Enrollment
400 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2025-05-14
Primary completion
2027-11
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Drugs
Indications
Sponsors
Vanda PharmaceuticalsLead Sponsor
Sites
22 total
Rogers, United StatesCosta Mesa, United StatesLemon Grove, United StatesOceanside, United StatesPico Rivera, United StatesSan Diego, United StatesWalnut Creek, United StatesNorth Miami, United StatesAtlanta, United StatesPeachtree Corners, United StatesChicago, United StatesFlowood, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
400
Phase
PHASE3
Primary Completion Date
2027-11
Status
RECRUITING
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
indication
indication